Targeting Photoreceptors via Intravitreal Delivery Using Novel, Capsid-Mutated AAV Vectors
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Development of viral vectors capable of transducing photoreceptors by less invasive methods than subretinal injection would provide a major advancement in retinal gene therapy. We sought to develop novel AAV vectors optimized for photoreceptor transduction following intravitreal delivery and to develop methodology for quantifying this transduction in vivo. Surface exposed tyrosine (Y) and threonine (T) residues on the capsids of AAV2, AAV5 and AAV8 were changed to phenylalanine (F) and valine (V), respectively. Transduction efficiencies of self-complimentary, capsid-mutant and unmodified AAV vectors containing the smCBA promoter and mCherry cDNA were initially scored in vitro using a cone photoreceptor cell line. Capsid mutants exhibiting the highest transduction efficiencies relative to unmodified vectors were then injected intravitreally into transgenic mice constitutively expressing a Rhodopsin-GFP fusion protein in rod photoreceptors (Rho-GFP mice). Photoreceptor transduction was quantified by fluorescent activated cell sorting (FACS) by counting cells positive for both GFP and mCherry. To explore the utility of the capsid mutants, standard, (non-self-complementary) AAV vectors containing the human rhodopsin kinase promoter (hGRK1) were made. Vectors were intravitreally injected in wildtype mice to assess whether efficient expression exclusive to photoreceptors was achievable. To restrict off-target expression in cells of the inner and middle retina, subsequent vectors incorporated multiple target sequences for miR181, an miRNA endogenously expressed in the inner and middle retina. Results showed that AAV2 containing four Y to F mutations combined with a single T to V mutation (quadY-F+T-V) transduced photoreceptors most efficiently. Robust photoreceptor expression was mediated by AAV2(quadY-F+T-V) -hGRK1-GFP. Observed off-target expression was reduced by incorporating target sequence for a miRNA highly expressed in inner/middle retina, miR181c. Thus we have identified a novel AAV vector capable of transducing photoreceptors following intravitreal delivery to mouse. Furthermore, we describe a robust methodology for quantifying photoreceptor transduction from intravitreally delivered AAV vectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since surface-exposed residues on AAV capsids can be ubiquitinated through phosphorylation, mutations of these residues (e.g. tyrosine, lysine, serine) to reduce the likelihood of ubiquitination can generate novel capsids with reduced ubiquitination, antigen presentation, and activated cellular immunity (92 -99).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [95]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Clinical trials for RPE65-Leber congenital amaurosis (LCA) have demonstrated the ability to deliver therapeutic transgene to the retinal pigment epithelium (RPE) by subretinal injection thereby restoring retinal function and visually-evoked behavior to patients [1–3].”
BackgroundSelf-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“Clinical trials for RPE65-Leber congenital amaurosis (LCA) have demonstrated the ability to deliver therapeutic transgene to the retinal pigment epithelium (RPE) by subretinal injection thereby restoring retinal function and visually-evoked behavior to patients [1–3].”
BackgroundSummerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406 · cited 7×
“In primate, the ILM is significantly thicker, except for an area in and around the fovea and immediately above large blood vessels [56].”
BackgroundInfluentialGene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“Several serotypes have been used to successfully target transgene to PRs following subretinal injection, including AAV2, AAV5 and AAV8 with all three demonstrating efficacy in proof of concept experiments across multiple species (mouse, rat, dog, pig and non-human primate) [8–21].”
MethodSelf-citation(1984) · PubMed · Cited by 1,200
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · cited 1×
“Adeno-associated virus (AAV) is considered the optimal vector for ocular gene therapy due to its efficiency, persistence and low immunogenicity [7].”
BackgroundRabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741 · cited 1×
“Promoter constructs were identical to those previously described [31,33,34].”
ResultJacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639 · cited 1×
“reported that subretinal injection under a cone-rich fovea resulted in decreased visual acuity (in some LCA2 patients) and foveal thinning (in both LCA2 patients and non-human primates) [5,6].”
BackgroundPhotoreceptor degeneration: genetic and mechanistic dissection of a complex trait
Wright, A. F., Chakarova, C. F., Abd El-Aziz, M. M., & Bhattacharya, S. S. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2717 · Cited by 631 · cited 1×
“Given the predominance of photoreceptor (PR) specific retinal degenerations [4], there is a need to develop PR targeted gene therapies.”
BackgroundProduction and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors
Zolotukhin, S., Potter, M., Zolotukhin, I., Sakai, Y., Loiler, S., Fraites, T. J., Chiodo, V. A., Phillipsberg, T., Muzyczka, N., Hauswirth, W. W., et al. (2002) · Methods · doi:10.1016/s1046-2023(02)00220-7 · Cited by 565
Self-citationZhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558 · cited 1×
“Selected tyrosine residues were mutated to phenylalanine (Y2F) whereas threonine residues were mutated to valine (T2V) [27].”
MethodSelf-citationAkache, B., Grimm, D., Pandey, K., Yant, S. R., Xu, H., & Kay, M. A. (2006) · Journal of Virology · doi:10.1128/jvi.00878-06 · Cited by 430
Kaludov, N., Brown, K. E., Walters, R. W., Zabner, J., & Chiorini, J. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6884-6893.2001 · Cited by 427
Auricchio, A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.26.3075 · Cited by 403 · cited 1×
“Several serotypes have been used to successfully target transgene to PRs following subretinal injection, including AAV2, AAV5 and AAV8 with all three demonstrating efficacy in proof of concept experiments across multiple species (mouse, rat, dog, pig and non-human primate) [8–21].”
MethodHigh-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398
Self-citationInner limiting membrane barriers to aav-mediated retinal transduction from the vitreous
Dalkara, D., Kolstad, K. D., Caporale, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.181 · Cited by 357 · cited 6×
“The internal limiting membrane (ILM) which defines the border between the retina and vitreous acts as a physical and biological barrier to AAV transduction following intravitreal injection in rodent and non-human primate retina [44,45].”
BackgroundResultInfluentialTan, E., Ding, X.-Q., Saadi, A., Agarwal, N., Naash, M. I., & Al-Ubaidi, M. R. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-1114 · Cited by 345 · cited 1×
“661W cone cells[36] (generously provided by Dr.”
Cideciyan, A. V., Hauswirth, W. W., Aleman, T. S., Kaushal, S., Schwartz, S. B., Boye, S. L., Windsor, E. A. M., Conlon, T. J., Sumaroka, A., Pang, J.-J., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.086 · Cited by 312 · cited 1×
“Clinical trials for RPE65-Leber congenital amaurosis (LCA) have demonstrated the ability to deliver therapeutic transgene to the retinal pigment epithelium (RPE) by subretinal injection thereby restoring retinal function and visually-evoked behavior to patients [1–3].”
BackgroundSelf-citationNovel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267 · cited 5×
“We previously showed that AAV2 and AAV8 vectors containing point mutations of surface-exposed tyrosine residues (tyrosine to phenylalanine,Y2F) display increased transgene expression in a variety of retinal cell types relative to unmodified vectors following both subretinal and intravitreal injection [25,26].”
BackgroundMethodInfluentialSelf-citationGene transfer into the mouse retina mediated by an adeno-associated viral vector
Ali, R. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.5.591 · Cited by 255 · cited 1×
“Several serotypes have been used to successfully target transgene to PRs following subretinal injection, including AAV2, AAV5 and AAV8 with all three demonstrating efficacy in proof of concept experiments across multiple species (mouse, rat, dog, pig and non-human primate) [8–21].”
MethodNovel adeno-associated virus serotypes efficiently transduce murine photoreceptors
Allocca, M., Mussolino, C., Garcia-Hoyos, M., Sanges, D., Iodice, C., Petrillo, M., Vandenberghe, L. H., Wilson, J. M., Marigo, V., Surace, E. M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01327-07 · Cited by 246 · cited 2×
“Several serotypes have been used to successfully target transgene to PRs following subretinal injection, including AAV2, AAV5 and AAV8 with all three demonstrating efficacy in proof of concept experiments across multiple species (mouse, rat, dog, pig and non-human primate) [8–21].”
BackgroundMethodBennett, J., Maguire, A. M., Cideciyan, A. V., Schnell, M., Glover, E., Anand, V., Aleman, T. S., Chirmule, N., Gupta, A. R., Huang, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9920 · Cited by 242 · cited 1×
“Several serotypes have been used to successfully target transgene to PRs following subretinal injection, including AAV2, AAV5 and AAV8 with all three demonstrating efficacy in proof of concept experiments across multiple species (mouse, rat, dog, pig and non-human primate) [8–21].”
MethodDosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey
Vandenberghe, L. H., Bell, P., Maguire, A. M., Cearley, C. N., Xiao, R., Calcedo, R., Wang, L., Castle, M. J., Maguire, A. C., Grant, R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002103 · Cited by 242 · cited 1×
“Several serotypes have been used to successfully target transgene to PRs following subretinal injection, including AAV2, AAV5 and AAV8 with all three demonstrating efficacy in proof of concept experiments across multiple species (mouse, rat, dog, pig and non-human primate) [8–21].”
MethodJacobson, S. G., Acland, G. M., Aguirre, G. D., Aleman, T. S., Schwartz, S. B., Cideciyan, A. V., Zeiss, C. J., Komaromy, A. M., Kaushal, S., Roman, A. J., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.005 · Cited by 224 · cited 2×
“All vectors were packaged, purified, and titered according to previously described methods [6,35].”
BackgroundMethodSelf-citationIntravitreal injection of AAV2 transduces macaque inner retina
Yin, L., Greenberg, K., Hunter, J. J., Dalkara, D., Kolstad, K. D., Masella, B. D., Wolfe, R., Visel, M., Stone, D., Libby, R. T., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6250 · Cited by 212 · cited 1×
“The internal limiting membrane (ILM) which defines the border between the retina and vitreous acts as a physical and biological barrier to AAV transduction following intravitreal injection in rodent and non-human primate retina [44,45].”
BackgroundKlimczak, R. R., Koerber, J. T., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007467 · Cited by 210 · cited 2×
“In the retina, this technology was used to identify a variant capable of specifically transducing Muller cells via the vitreous [39].”
BackgroundMethodYang, G. S., Schmidt, M., Yan, Z., Lindbloom, J. D., Harding, T. C., Donahue, B. A., Engelhardt, J. F., Kotin, R., & Davidson, B. L. (2002) · Journal of Virology · doi:10.1128/jvi.76.15.7651-7660.2002 · Cited by 204
Weber, M., Rabinowitz, J., Provost, N., Conrath, H., Folliot, S., Briot, D., Chérel, Y., Chenuaud, P., Samulski, J., Moullier, P., et al. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00098-4 · Cited by 203
Directed evolution of novel adeno-associated viruses for therapeutic gene delivery
Bartel, M. A., Weinstein, J. R., & Schaffer, D. V. (2012) · Gene Therapy · doi:10.1038/gt.2012.20 · Cited by 162 · cited 2×
“Directed evolution has been applied to select AAV variants from combinatorial libraries that demonstrate a diverse range of cellular tropisms in vivo relative to their parent serotypes [43].”
BackgroundmiRNeye: a microRNA expression atlas of the mouse eye
Karali, M., Peluso, I., Gennarino, V. A., Bilio, M., Verde, R., Lago, G., Dollé, P., & Banfi, S. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-715 · Cited by 155 · cited 1×
“A microRNA expression atlas of the mouse eye [55] indicates that miR-181c is highly expressed in retinal ganglion cells and middle retina and absent in photoreceptors in P60 mouse (http://mirneye.”
BackgroundPang, J.-J., Dai, X., Boye, S. E., Barone, I., Boye, S. L., Mao, S., Everhart, D., Dinculescu, A., Liu, L., Umino, Y., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.273 · Cited by 148 · cited 1×
“showed that incorporation of these mutations led to more pronounced rescue in animal models of inherited retinal disease [23,42] and in one case, conferred therapy in a particularly aggressive mouse model that was refractory to treatment using an unmodified parent serotype [24].”
BackgroundSelf-citationKhani, S. C., Pawlyk, B. S., Bulgakov, O. V., Kasperek, E., Young, J. E., Adamian, M., Sun, X., Smith, A. J., Ali, R. R., & Li, T. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-0257 · Cited by 139
Boye, S. E., Alexander, J. J., Boye, S. L., Witherspoon, C. D., Sandefer, K. J., Conlon, T. J., Erger, K., Sun, J., Ryals, R., Chiodo, V. A., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.125 · Cited by 117 · cited 11×
“Previous studies evaluating GRK1 promoter activity in retina have utilized AAV serotypes with poor tropism for retinal ganglion cells, namely AAV5 and AAV8 [18,23,31,53,54].”
BackgroundResultInfluentialSelf-citationAAV-Mediated Cone Rescue in a Naturally Occurring Mouse Model of CNGA3-Achromatopsia
Pang, J.-J., Deng, W.-T., Dai, X., Lei, B., Everhart, D., Umino, Y., Li, J., Zhang, K., Mao, S., Boye, S. L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035250 · Cited by 114 · cited 1×
“showed that incorporation of these mutations led to more pronounced rescue in animal models of inherited retinal disease [23,42] and in one case, conferred therapy in a particularly aggressive mouse model that was refractory to treatment using an unmodified parent serotype [24].”
BackgroundSelf-citationLotery, A. J., Yang, G. S., Mullins, R. F., Russell, S. R., Schmidt, M., Stone, E. M., Lindbloom, J. D., Chiorini, J. A., Kotin, R. M., & Davidson, B. L. (2003) · Human Gene Therapy · doi:10.1089/104303403322542301 · Cited by 107
AAV-mediated photoreceptor transduction of the pig cone-enriched retina
Mussolino, C., della Corte, M., Rossi, S., Viola, F., Di Vicino, U., Marrocco, E., Neglia, S., Doria, M., Testa, F., Giovannoni, R., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.3 · Cited by 102
Beltran, W. A., Boye, S. L., Boye, S. E., Chiodo, V. A., Lewin, A. S., Hauswirth, W. W., & Aguirre, G. D. (2010) · Gene Therapy · doi:10.1038/gt.2010.56 · Cited by 96
Self-citationLi, C., Diprimio, N., Bowles, D. E., Hirsch, M. L., Monahan, P. E., Asokan, A., Rabinowitz, J., Agbandje-McKenna, M., & Samulski, R. J. (2012) · Journal of Virology · doi:10.1128/jvi.00675-12 · Cited by 96 · cited 1×
“These approaches have led to identification of novel capsids with increased transduction efficiency [25] altered tropism [26,39,40] and the ability to evade recognition by the immune system [41].”
BackgroundSelf-citationAslanidi, G. V., Rivers, A. E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., & Srivastava, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059142 · Cited by 95
Self-citationBoye, S. E., Boye, S. L., Pang, J., Ryals, R., Everhart, D., Umino, Y., Neeley, A. W., Besharse, J., Barlow, R., & Hauswirth, W. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011306 · Cited by 94 · cited 7×
“Previous studies evaluating GRK1 promoter activity in retina have utilized AAV serotypes with poor tropism for retinal ganglion cells, namely AAV5 and AAV8 [18,23,31,53,54].”
BackgroundInfluentialSelf-citationGabriel, N., Hareendran, S., Sen, D., Gadkari, R. A., Sudha, G., Selot, R., Hussain, M., Dhaksnamoorthy, R., Samuel, R., Srinivasan, N., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.194 · Cited by 90
Stieger, K., Colle, M.-A., Dubreil, L., Mendes-Madeira, A., Weber, M., Le Meur, G., Deschamps, J. Y., Provost, N., Nivard, D., Cherel, Y., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.41 · Cited by 75 · cited 1×
“Several serotypes have been used to successfully target transgene to PRs following subretinal injection, including AAV2, AAV5 and AAV8 with all three demonstrating efficacy in proof of concept experiments across multiple species (mouse, rat, dog, pig and non-human primate) [8–21].”
MethodHaire, S. E., Pang, J., Boye, S. L., Sokal, I., Craft, C. M., Palczewski, K., Hauswirth, W. W., & Semple-Rowland, S. L. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0086 · Cited by 66 · cited 1×
“Promoter constructs were identical to those previously described [31,33,34].”
ResultSelf-citationRaupp, C., Naumer, M., Müller, O. J., Gurda, B. L., Agbandje-McKenna, M., & Kleinschmidt, J. A. (2012) · Journal of Virology · doi:10.1128/jvi.00209-12 · Cited by 64
Self-citationBoye, S. L., Conlon, T., Erger, K., Ryals, R., Neeley, A., Cossette, T., Pang, J., Dyka, F. M., Hauswirth, W. W., & Boye, S. E. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-7867 · Cited by 63 · cited 11×
“Previous studies evaluating GRK1 promoter activity in retina have utilized AAV serotypes with poor tropism for retinal ganglion cells, namely AAV5 and AAV8 [18,23,31,53,54].”
BackgroundMethodInfluentialSelf-citationMicroRNA-Restricted Transgene Expression in the Retina
Karali, M., Manfredi, A., Puppo, A., Marrocco, E., Gargiulo, A., Allocca, M., Corte, M. D., Rossi, S., Giunti, M., Bacci, M. L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022166 · Cited by 60 · cited 1×
“Similar to methods previously described, [32] we further restricted transgene expression to PRs by incorporating multiple target sequences for miR181, an miRNA endogenously expressed in cells of the inner and middle retina.”
MethodAslanidi, G. V., Rivers, A. E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G. R., Zolotukhin, S., Agbandje-McKenna, M., & Srivastava, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.03.079 · Cited by 48
Self-citationPetersen‐Jones, S. M., Bartoe, J. T., Fischer, A. J., Scott, M. A., Boye, S. L., Chiodo, V. A., & Hauswirth, W. W. (2009) · PubMed Central · Cited by 42
Self-citation(2011) · PubMed Central · Cited by 41
Self-citationProteomics Profiling of the Cone Photoreceptor Cell Line, 661W
Al‐Ubaidi, M. R., Matsumoto, H., Kurono, S., & Singh, A. K. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-74904-4_35 · Cited by 25 · cited 1×
“Cultures were incubated at 37uC [38].”
Expression pattern of Glycoconjugates in Rat Retina as Analysed by Lectin Histochemistry
Cho, E. Y. P., Choi, H., & Chan, F. L. (2003) · The Histochemical Journal · doi:10.1023/a:1026032005521 · Cited by 24 · cited 7×
“In primate, the ILM is significantly thicker, except for an area in and around the fovea and immediately above large blood vessels [56].”
BackgroundInfluentialChai, L., & Morris, J. E. (1994) · Current Eye Research · doi:10.3109/02713689408999903 · Cited by 20 · cited 7×
“In primate, the ILM is significantly thicker, except for an area in and around the fovea and immediately above large blood vessels [56].”
BackgroundInfluentialPeptide affinity reagents for AAV capsid recognition and purification
Pulicherla, N., & Asokan, A. (2011) · Gene Therapy · doi:10.1038/gt.2011.46 · Cited by 15 · cited 1×
“These approaches have led to identification of novel capsids with increased transduction efficiency [25] altered tropism [26,39,40] and the ability to evade recognition by the immune system [41].”
BackgroundRhodopsin–EGFP knock-ins for imaging quantal gene alterations
Wensel, T. G., Gross, A. K., Chan, F., Sykoudis, K., & Wilson, J. H. (2005) · Vision Research · doi:10.1016/j.visres.2005.07.016 · Cited by 14
Cone And Rod Transduction With Alternative AAV Serotypes In The Macula Of Non-human Primates
Vandenberghe, L. H., Bell, P. L., Maguire, A. M., Xiao, R., McMenamin, D., Munden, R. L., Grant, R. L., Bennett, J., & Wilson, J. M. (2011) · Investigative Ophthalmology & Visual Science · Cited by 4
Cited by
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“The capsid choice in this trial was dictated by transduction observed in the XLRS mouse model and perhaps the expectation that the presence of schisis cavities in XLRS patient retinas would facilitate transduction.(128) Taken together, the lack of efficacy in this trial was at least partially due to inefficient target…”
BackgroundSelf-citationAAV-Mediated Gene Therapy for Research and Therapeutic Purposes
Samulski, R. J., & Muzyczka, N. (2014) · Annual Review of Virology · doi:10.1146/annurev-virology-031413-085355 · Cited by 551
Dias, M. F., Joo, K., Kemp, J. A., Fialho, S. L., da Silva Cunha, A., Woo, S. J., & Kwon, Y. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.004 · Cited by 413
Progresses towards safe and efficient gene therapy vectors
Chira, S., Jackson, C. S., Oprea, I., Ozturk, F., Pepper, M. S., Diaconu, I., Braicu, C., Raduly, L.-Z., Calin, G. A., & Berindan-Neagoe, I. (2015) · Oncotarget · doi:10.18632/oncotarget.5169 · Cited by 219
“Optimal transduction efficiency can further be obtained through combinational mutagenesis of the surface-exposed Y and T residues [115] [116].”
BackgroundMacé, E., Caplette, R., Marre, O., Sengupta, A., Chaffiol, A., Barbe, P., Desrosiers, M., Bamberg, E., Sahel, J.-A., Picaud, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.154 · Cited by 197
“To overcome these hurdles, new AAV variants with the ability to deliver genes deep into the retina via intravitreal route have been engineered 20-22 .”
Metadata
- Authors
- Kay, C. N., Ryals, R. C., Aslanidi, G. V., Min, S. H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D., Ayala, A. E., Van Vliet, K., Agbandje-McKenna, M., Hauswirth, W. W., Boye, S. L., & Boye, S. E.
- Affiliations
- University of Florida Health (US)
- Corresponding author
- Boye, Shannon E.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-04-26
- Volume
- 8
- Issue
- 4
- Pages
- e62097
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3637363
- OpenAlex
- W2067733824
- Cited by
- 168
- References
- 56
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 1 · 2023: 7 · 2022: 11 · 2021: 14 · 2020: 17 · 2019: 16 · 2018: 19 · 2017: 14 · 2016: 21 · 2015: 24 · 2014: 11 · 2013: 5
- FWCI
- 13.48
- Type
- journal article
- Language
- en
- Update notices
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Foundation Fighting Blindness
- Research to Prevent Blindness
- National Eye Institute (P30EY021721, R01EY017549, R24EY022012)
- National Institute of General Medical Sciences (R01GM082946)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, capsid mutations, phototransduction, intravitreal delivery, retinal gene therapy, AAV2, AAV5, AAV8, off-target expression, cone photoreceptors, rod photoreceptors
- MeSH terms
- Dependovirus, Animals, Capsid, Cell Line, Chickens, Genetic Vectors, Humans, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Promoter Regions, Genetic, Serotyping, Transduction, Genetic, Gene Expression, Gene Transfer Techniques, Transgenes, Photoreceptor Cells, Vertebrate, MicroRNAs, Mice, G-Protein-Coupled Receptor Kinase 1, Viral Tropism, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.